https://www.selleckchem.com/pr....oducts/emd-1214063.h
Patients with tumors BRAFwt/TERTpmut (HR = 24.2, p less then 0.001) and BRAFmut/TERTpmut (HR = 11.5, p = 0.002) showed increased risk of structural disease. DSM was significantly increased in patients with TERTpmut regardless of BRAF status (BRAFmut/TERTpmut, log-rank p less then 0.001; BRAFwt/TERTpmut, log-rank p less then 0.001). Our results indicate that molecular markers may have a role in predicting PTC patients' outcome. BRAFmut/TERTpwt tumors were prone to associate with local aggressiveness (recurrent/persistent disease), wh
Like
Comment
Share
